An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 30 July 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12, 698148
Abstract
Ninety-five percent of the population are estimated to carry at least one genetic variant that is discordant with at least one medication. Pharmacogenomic (PGx) testing has the potential to identify patients with genetic variants that puts them at risk of adverse drug reactions and sub-optimal therapy. Predicting a patient's response to medications could support the safe management of medications and reduce hospitalization. These benefits can only be realized if prescribing clinicians make the medication changes prompted by PGx test results. This review examines the current evidence on the impact PGx testing has on hospital admissions and whether it prompts medication changes. A systematic search was performed in three databases (Medline, CINAHL and EMBASE) to search all the relevant studies published up to the year 2020, comparing hospitalization rates and medication changes amongst PGx tested patients with patients receiving treatment-as-usual (TAU). Data extracted from full texts were narratively synthesized using a process model developed from the included studies, to derive themes associated to a suggested workflow for PGx-guided care and its expected benefit for medications optimization and hospitalization. A meta-analysis was undertaken on all the studies that report the number of PGx tested patients that had medication change(s) and the number of PGx tested patients that were hospitalized, compared to participants that received TAU. The search strategy identified 5 hospitalization themed studies and 5 medication change themed studies for analysis. The meta-analysis showed that medication changes occurred significantly more frequently in the PGx tested arm across 4 of 5 studies. Meta-analysis showed that all-cause hospitalization occurred significantly less frequently in the PGx tested arm than the TAU. The results show proof of concept for the use of PGx in prescribing that produces patient benefit. However, the review also highlights the opportunities and evidence gaps that are important when considering the introduction of PGx into health systems; namely patient involvement in PGx prescribing decisions, thus a better understanding of the perspective of patients and prescribers. We highlight the opportunities and evidence gaps that are important when considering the introduction of PGx into health systems.Keywords
Funding Information
- University of Bradford
This publication has 52 references indexed in Scilit:
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Pharmacogenomics of adverse drug reactions: implementing personalized medicineHuman Molecular Genetics, 2012
- Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatmentGenome Medicine, 2011
- Warfarin Genotyping Reduces Hospitalization RatesJACC, 2010
- Outlier and influence diagnostics for meta-analysisResearch Synthesis Methods, 2010
- A typology of reviews: an analysis of 14 review types and associated methodologiesHealth Information & Libraries Journal, 2009
- Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in GreeceEuropean Journal of Internal Medicine, 2008
- Systematic Review of the Effects of Shared Decision-Making on Patient Satisfaction, Treatment Adherence and Health StatusPsychotherapy and Psychosomatics, 2008
- Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationThe Pharmacogenomics Journal, 2006
- A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trialsStatistics in Medicine, 2002